The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes

202140 citationsJournal Articlebronze Open Access

Authors

Klara R. Klein · University of North Carolina at Chapel Hill

Jennifer L. R. Freeman · vTv Therapeutics (United States)

Imogene Dunn · vTv Therapeutics (United States)

Chris Dvergsten · vTv Therapeutics (United States)

M. Sue Kirkman · University of North Carolina at Chapel Hill

John B. Buse · University of North Carolina at Chapel Hill

Carmen Valcarce

Abstract

TTP399 lowers HbA<sub>1c</sub> and reduces hypoglycemia without increasing the risk of ketosis and should be further evaluated as an adjunctive therapy for the treatment of type 1 diabetes.

Topics & Keywords

Pancreatic function and diabetes Diabetes Management and Research Diabetes and associated disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 44, Issue 4, pp. 960-968

DOI: 10.2337/dc20-2684

Field-Weighted Citation Impact: 5.85